Clinical TrialsPCS6422 has previously generated positive signals of a favorable risk-reward profile, limiting adverse events.
Drug DevelopmentNGC-Iri, an analog of SN-38, showed a more favorable adverse event profile and greater efficacy in preclinical models compared to existing treatments, indicating potential improvements in cancer therapy.
FundraisingProcessa completed a $5M public offering, which is believed to be sufficient to fund the company into 2H25.